{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219500","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2026-05-12T20:17:24+00:00","discovered_at":"2026-05-12T20:19:00.336182+00:00","generated_at":"2026-05-12T20:39:36.099678+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AnaptysBio Q1 net loss $52.9M; completes First Tracks spin-off, Jemperli royalties up 44%","bullets":["Net loss per share $1.84 vs $1.28 YoY; collaboration revenue $25.6M (Jemperli royalties $24.7M, +44%).","Cash $286.5M at March 31; stock repurchase plan of $100M authorized through Dec 31, 2026.","Spin-off of First Tracks Bio completed Apr 20; now exclusively manages Jemperli (GSK) and imsidolimab (Vanda) financial collaborations.","Expects >$390M annualized Jemperli royalties by 2029 at GSK's >$2.7B peak sales; Sagard debt paydown by Q2 2027.","FDA PDUFA Dec 12, 2026 for imsidolimab in GPP; Chris Murphy appointed CFO, Susannah Gray and Owen Hughes to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219500","json":"https://secwatch.observer/filing/0001193125-26-219500.json","markdown":"https://secwatch.observer/filing/0001193125-26-219500.md","text":"https://secwatch.observer/filing/0001193125-26-219500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/0001193125-26-219500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T20:39:36.099678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}